North America Central Precocious Puberty (CPP) Treatment Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Sep 2020
  • North America
  • 350 Pages
  • No of Tables: 109
  • No of Figures: 45

North America Central Precocious Puberty (CPP) Treatment Market, By Type (Medication, Surgery), Month (1-Month, 2-Month, 6-Month, Others), Route of Administration (Parenteral, Implants, Oral, Others), Gender (Girls, Boys), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), Country (U.S., Canada, Mexico) Industry Trends & Forecast to 2027

North America Central Precocious Puberty (CPP) Treatment Market Market Analysis and Insights : North America Central Precocious Puberty (CPP) Treatment Market

North America central precocious puberty (CPP) treatment market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.2% in the forecast period of 2020 to 2027 and is expected to reach Euro 382.04 million by 2027 from Euro 223.01 million in 2019. Increasing global healthcare expenditure and growing prevalence of hormonal disorders are the major drivers which propelled the demand of the market in the forecast period.

Central precocious puberty (CPP) treatment comprises features such as presence of novel pipeline drugs which will impact in launching new product by the manufactures into the market which enhance its demand as well as high demand of disease specific treatment leads the demand of accurate central precocious puberty (CPP) treatment. Currently various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative central precocious puberty (CPP) treatment which is expected to provide various other opportunities in the central precocious puberty (CPP) treatment market. However, patent expiry and existence of alternative treatment methods expected to restraint the market growth in the forecast period.

The demand for central precocious puberty (CPP) treatment has been increased in both developed as well as in developing countries and the reason behind this is growing prevalence of obesity and hormonal disorders around the world. The central precocious puberty (CPP) treatment market will grow in the forecast period due to the presence of strong product pipeline, launch of awareness campaign and availability of off label drugs.

High treatment costs, adverse effects associated with drugs administered and complications associated with diagnosis of central precocious puberty (CPP) are expected to restrain the central precocious puberty (CPP) treatment market growth.

The central precocious puberty (CPP) treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

North America Central Precocious Puberty (CPP) Treatment Market North America Central Precocious Puberty (CPP) Treatment Market Scope and Market Size

Central precocious puberty (CPP) treatment market is categorized into six notable segments which are type, months, route of administration, gender, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of type, the central precocious puberty (CPP) treatment market is segmented into medication and surgery. In 2020, medication segment is expected to dominate the market, as medicines are the first line of therapy for central precocious puberty (CPP) treatment.
  • On the basis of month, the central precocious puberty (CPP) treatment market is segmented into 1-month, 3-month, 6-month, and others. In 2020, 1-month segment is dominating in the central precocious puberty (CPP) treatment market because children diagnosed with CPP are at first prescribed with 1- month drug dosage in order to monitor the effects and efficacy of administered drug.
  • On the basis of route of administration, the central precocious puberty (CPP) treatment market is segmented into parenteral, oral, implants, others. In 2020, parenteral segment is dominating in the central precocious puberty (CPP) treatment market because as medicines used for CPP treatment have sustained release formulations and also required prolonged administration that is achieved by injection of GnRH.
  • On the basis of gender, the central precocious puberty (CPP) treatment market is segmented into girls and boys. In 2020, girls segment is dominating in the central precocious puberty (CPP) treatment market because large population of girls have been reported to affected by CPP as compared to that of the boys.
  • On the basis of end user, the central precocious puberty (CPP) treatment market is segmented into hospitals, specialty clinics, homecare, and others. In 2020, hospitals segment is dominating in the central precocious puberty (CPP) treatment market as the hospitals provides with advanced diagnostic devices and offers best surgical treatment for central precocious puberty.
  • On the basis of distribution channel, the central precocious puberty (CPP) treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. In 2020, direct tender segment is dominating in the market as most of the healthcare facilities procure drugs through direct tender in bulk amount at an effective cost price.

Central Precocious Puberty (CPP) Treatment Market Country Level Analysis

Central precocious puberty (CPP) treatment market is categorized into six notable segments which are based on the basis of type, months, route of administration, gender, end user and distribution channel as referenced above.

The countries covered in the central precocious puberty (CPP) treatment market report are the U.S., Canada, and Mexico.

North America region is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 because of increasing clinical trials and research development for prevention of hormonal misbalance among the children. The U.S. is dominating the market because of the increasing prevalence of obesity leading to early puberty among the children.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Increasing Cases of Granulosa Cell Tumors and Presence of Strong Product Pipeline are Boosting the Market Growth of Central Precocious Puberty (CPP) Treatment

Central precocious puberty (CPP) treatment market also provides you with detailed market analysis for every country growth in central precocious puberty (CPP) treatment industry with central precocious puberty (CPP) treatment drugs sales, impact of advancement in the central precocious puberty (CPP) treatment technology and changes in regulatory scenarios with their support for the central precocious puberty (CPP) treatment market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Central precocious puberty (CPP) Treatment Market Share Analysis

Central precocious puberty (CPP) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to central precocious puberty (CPP) treatment market.

The major companies which are dealing in the central precocious puberty (CPP) treatment are Ipsen Pharma, AbbVie Inc., Mylan N.V., Pfizer Inc., Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Teva Pharmaceutical USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.), Takeda Pharmaceutical Company Limited, Sanofi, Arbor Pharmaceuticals, Tolmar Pharmaceuticals, Inc., DAEWOONG PHARMACEUTICAL CO.,LTD, AstraZeneca, Sun Pharmaceutical Industries Ltd, Endo International plc among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the central precocious puberty (CPP) treatment market.

For instance,

  • In February, 2018 Ipsen Pharma went under strategic partnership with Arix Bioscience so as to advance its specialty care product portfolio. The company is offering central precocious puberty treatment through its specialty care business, hence this agreement helped it to develop and commercialize innovative medicines for patients suffering from rare disease.
  • In March, 2016 Teva Pharmaceutical Industries Ltd. received approval from European Commission for acquisition of Allergan Generics business. According to this approval the company has manufactured and marketed generic medicines involving medicines used for central precocious puberty treatment, which has enhanced the company’s revenue.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the central precocious puberty (CPP) treatment market which also provides the benefit for organization to improve their offering for central precocious puberty (CPP) treatment.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES 

TABLE 1 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 GENERIC DRUGS FOR CENTRAL PRECOCIOUS PUBERTY

TABLE 3 MEDICINES SUBJECTED TO PATENT EXPIRY

TABLE 4 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE, 2019-2027 (EURO MILLION)

TABLE 5 NORTH AMERICA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 6 NORTH AMERICA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 7 NORTH AMERICA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 8 NORTH AMERICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 9 NORTH AMERICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 10 NORTH AMERICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 11 NORTH AMERICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 12 NORTH AMERICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 13 NORTH AMERICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 14 NORTH AMERICA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 15 NORTH AMERICA SURGERIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 16 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH, 2019-2027 (EURO MILLION)

TABLE 17 NORTH AMERICA 1- MONTH IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 18 NORTH AMERICA 3- MONTH IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 19 NORTH AMERICA 6- MONTH IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 20 NORTH AMERICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 21 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (EURO MILLION)

TABLE 22 NORTH AMERICA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 23 NORTH AMERICA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 24 NORTH AMERICA ORAL IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 25 NORTH AMERICA IMPLANT IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 26 NORTH AMERICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 27 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER, 2019-2027 (EURO MILLION)

TABLE 28 NORTH AMERICA GIRLS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 29 NORTH AMERICA BOYS IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 30 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER, 2019-2027 (EURO MILLION)

TABLE 31 NORTH AMERICA HOSPITALS IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 32 NORTH AMERICA SPECILATY CLINICS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 33 NORTH AMERICA HOME CARE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 34 NORTH AMERICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 35 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (EURO MILLION)

TABLE 36 NORTH AMERICA DIRECT TENDER IN CENTRAL PRECOCIOUS PUBERTY (CPP)TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 37 NORTH AMERICA HOSPITAL PHARMACIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 38 NORTH AMERICA RETAIL PHARMACIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 39 NORTH AMERICA ONLINE PHARMACIES IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2017-2027 (EURO MILLION)

TABLE 40 NORTH AMERICA OTHERS IN CNETRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY REGION, 2018-2027 (EURO MILLION)

TABLE 41 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY COUNTRY, 2018-2027 (EURO MILLION)

TABLE 42 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 43 NORTH AMERICA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 44 NORTH AMERICA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 45 NORTH AMERICA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 46 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 47 NORTH AMERICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 48 NORTH AMERICA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 49 NORTH AMERICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 50 NORTH AMERICA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 51 NORTH AMERICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 52 NORTH AMERICA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 53 NORTH AMERICA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 54 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 55 NORTH AMERICA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 56 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 57 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 58 NORTH AMERICA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 59 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 60 U.S. MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 61 U.S. LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 62 U.S. ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 63 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 64 U.S. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 65 U.S. LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 66 U.S. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 67 U.S. HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 68 U.S. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 69 U.S. TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 70 U.S. OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 71 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 72 U.S. PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 73 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 74 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 75 U.S. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 76 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 77 CANADA MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 78 CANADA LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 79 CANADA ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 80 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 81 CANADA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 82 CANADA LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 83 CANADA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 84 CANADA HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 85 CANADA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 86 CANADA TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 87 CANADA OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 88 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 89 CANADA PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 90 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 91 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 92 CANADA CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

TABLE 93 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 94 MEXICO MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 95 MEXICO LONG-ACTING ANALOGS OF GNRH (GONADOTROPHIN-RELEASING HORMONES) MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 96 MEXICO ADJUNCTIVE TREATMENTS MEDICATION IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY TYPE 2018-2027 (EURO MILLION)

TABLE 97 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 98 MEXICO LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 99 MEXICO LEUPROLIDE ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 100 MEXICO HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 101 MEXICO HISTRELIN ACETATE IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 102 MEXICO TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 103 MEXICO TRIPTORELIN IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (UNITS)

TABLE 104 MEXICO OTHERS IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY MONTH 2018-2027 (EURO MILLION)

TABLE 105 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 106 MEXICO PARENTERAL IN CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2018-2027 (EURO MILLION)

TABLE 107 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY GENDER 2018-2027 (EURO MILLION)

TABLE 108 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY END USER 2018-2027 (EURO MILLION)

TABLE 109 MEXICO CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2018-2027 (EURO MILLION)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19